Serum levels of bleomycin released from the lymphatic system

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery Systems

Background:

• Residual retroperitoneal malignant lymphoma often requires targeted treatment post-chemotherapy.
• Bleomycin is a chemotherapy agent used in various cancers, typically administered intravenously.
• Understanding drug pharmacokinetics is crucial for optimizing cancer therapy.

Purpose of the Study:

• To evaluate the pharmacokinetic profile of intralymphatic Oil-Bleo (bleomycin) in patients with residual retroperitoneal malignant lymphoma.
• To compare the serum concentration-time profile of intralymphatic bleomycin with that of conventional intravenous bleomycin administration.

Main Methods:

• Twenty-four patients with residual retroperitoneal malignant lymphoma received a single endolymphatic injection of Oil-Bleo.
• Dosage administered was 60 mg/30 mg per foot.
• Serum bleomycin levels were monitored over time and compared to historical data from intravenous bleomycin administration in cervical cancer patients.

Main Results:

• Intralymphatic bleomycin achieved maximum serum concentration rapidly, within 15 minutes post-administration.
• Intravenous bleomycin administration reached maximum serum concentration significantly later, at 36 hours.
• This indicates a substantially faster absorption and distribution of bleomycin via the intralymphatic route.

Conclusions:

• Endolymphatic injection of Oil-Bleo provides a rapid systemic exposure to bleomycin.
• This pharmacokinetic profile may offer advantages for treating localized or residual malignancies.
• Further research is warranted to explore the clinical efficacy and safety of intralymphatic bleomycin administration.